These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34284214)

  • 1. Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients.
    Mahgoub S; Abosalem H; Emara M; Kotb N; Maged A; Soror S
    Mol Immunol; 2021 Sep; 137():221-227. PubMed ID: 34284214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma.
    Abdelrahman MM; Fawzy IO; Bassiouni AA; Gomaa AI; Esmat G; Waked I; Abdelaziz AI
    Hum Immunol; 2016 Aug; 77(8):667-673. PubMed ID: 27262453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
    López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
    Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma.
    Watanabe M; Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Maruyama T; Izawa S; Fujii H
    Dis Esophagus; 2010 Nov; 23(8):675-81. PubMed ID: 20545975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early expansion of anergic NKG2A
    Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
    Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
    Loubeau M; Ahmad A; Toma E; Menezes J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
    Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
    J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
    Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
    Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
    Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
    Front Immunol; 2021; 12():798087. PubMed ID: 35058934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
    Tjwa ET; van Oord GW; Hegmans JP; Janssen HL; Woltman AM
    J Hepatol; 2011 Feb; 54(2):209-18. PubMed ID: 21095036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
    Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
    Front Immunol; 2021; 12():737311. PubMed ID: 34557197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.